Chips Draw Puts, Rocket Draws Calls on Index Watch
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
Semiconductor names dominated bearish options flow this week. NVDA, AMD, and MU all rank among the highest negative-bet volumes over the past seven days, according to ORTEX screening data. Micron saw the largest raw negative bets in the group. Its RSI has slipped to 37, and analysts still see 87% upside to their target price, a wide gap that options traders appear to be fading near term.
AAPL faces its own headwind. A fresh report flagged that Apple's slow break from QCOM is still hurting revenue, with handset revenue set to slip as Qualcomm lifts prices. AAPL options expiries cluster heavily around November 20 and December 18. That December date aligns with the S&P 500 December Quarterly Review trade date, adding an index-rebalance dimension to positioning.
The most striking shift is in RKT (Rocket Companies). Its S&P 500 addition probability jumped from 4% to 31% overnight on the ORTEX Index Rebalance Radar. ORTEX forecasts $4.1B of forced buying on the December 18 trade date if it is confirmed. Options scores for Rocket sit among the more bullish readings in the financial sector this week. At a DTC of 8.7, any addition announcement could compress shorts fast.
JOBY grabbed headlines after its CEO milestone news. Its RSI is a depressed 35. With a short score of 74.8 and analyst upside of 108%, the stock draws speculative call interest but remains heavily shorted.
On the broad market, SPY expiries through end-November are densely stacked. The MSCI World announcement on November 11, four sessions away, adds another catalyst for index-linked hedging ahead of the weekend.
Stocks in this article
How this article was generated
- Generated
- 5 Nov 2026, 08:43
- Prompt version
- v1.0
- Data sources
- Options flowORTEX Alpha signalsAlt DataIndex Rebalance
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.